Skip to main content

Table 2 Baseline clinical characteristics and TB incidence of HIV/AIDS patients who started ART from September 2007 to August 2008 at the University of Gondar Hospital

From: The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study

Variable

Total

Incident TB+

Incident TB-

Female sex (n[%])

258(64.5)

18(69.2)

240(64.2)

Age (years, mean [SD])

34.37 ± 9.29

35.4 ± 8.8

34.3 ± 9.3

WHO HIV clinical stage (n[%])

   

  I

57(14.3)

2(3.5)

55(96.5)

  II

86(21.5)

6(7.0)

80(93.0)

  III

208(52.0)

13(6.2)

195(93.8)

  IV

49(12.3)

5(10.2)

44(89.8)

CD4 count (cells/mm 3 , median [IQR])

152(82, 203)

98(58,201.75)

153(86,203)

CD4 count (cell/mm 3 , n[%])

   

  0-99

127(31.8)

13(10.4)

112(89.6)

  ≥100

170(42.5)

13(4.7)

262(95.3)

Initial ART Regimen (n[%])

   

  d4T/3TC/NVP or EFV

49(12.3)

4(8.2)

45(91.8)

  AZT/3TC/NVP or EFV

189(47.3)

15(7.9)

174(92.1)

  TDF/3TC/NVP or EFV

162(40.5)

7(4.3)

155(95.7)

Functional status (n[%])

   

  Working

340(85.0)

20(5.9)

320(94.1)

  Ambulatory

49(12.3)

4(8.2)

45(91.8)

  Bed ridden

11(2.8)

2(18.2)

9(81.8)

  1. d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz; TDF: tenofobir; TB: tuberculosis; HIV: human immunodeficiency virus; ART: antiretroviral therapy; IQR: interquartile range; SD: standard deviation; WHO: world health organization.